571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation

BACKGROUND: Letermovir (LTM) was FDA-approved in 2017 for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic cell transplant (HCT) patients. We evaluated the “real-world” impact of LTM in adult HCT recipients at the Mount Sinai Hospital in New York following addition of LTM to our formula...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Open Forum Infect Dis
Hoofdauteurs: Loecher, Alyssa M, Yum, Kendra, Park, Daniel, Kim, Sara, Saunders-Hao, Patricia, Jakubowski, Rita, Keyzner, Alla, Steinberg, Amir, Rana, Meenakshi, Jacobs, Samantha E
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2020
Onderwerpen:
Poster Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778032/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.765
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items